For AstraZenica's review only

HSJ CANCER FORUM

Rescheduled to Monday, 24 April 2023, Etc venues Houndsditch, Central London

08.15 – 09.15

Registration & refreshments

09.15 – 09.25

Opening remarks from the chair
Ben Clover, Bureau Chief, HSJ

09.25 – 9.55

Keynote: Implementing the National Cancer Strategy

• Achieving the key tenets of the long term strategy whilst recognising the system wide pressures and boosting the cancer workforce to deliver the plan
• Reducing variation and inequality in detection and care, putting patient experience at the forefront
• Fostering a culture of innovation in diagnostics and care to meet ambitious targets
• Tackling the ‘hidden pandemic’ by expanding capacity and adapting to meet growing demand year on year 

Dr Liz Bishop, Chief Executive of The Clatterbridge Cancer Centre and National Cancer Board Member 

9.55 – 10.35

Panel: What does a systems approach to cancer actually mean?

• Maximising the opportunities presented through ICSs in providing a holistic approach to cancer
• Examining the role which cancer alliances play in cancer care when the boundaries are non-coterminous with ICSs
• Expanding care in the community through innovative approaches in early diagnostics, screening and mobile care to reduce hospital pressures
• Enhancing access to specialised services in a cost-effective manner across ICS boundaries
• Overcoming challenges and competing pressures between providers which make up an Integrated Care Board 

Supported by Novartis

Marie-Andree Gamache, President & Managing Director, UK & Ireland, Novartis Pharmaceuticals UK

Claire O’Rourke, Managing Director, Greater Manchester Cancer Alliance

Professor David Shackley, Consultant Surgeon and Director, Northern Care Alliance NHS FT & Medical Director, Greater Manchester Cancer Alliance

Sarah Hughes, Managing Director, Cancer Alliances Midlands

Alastair Simpson, Medical Director and National Speciality Advisor for Cancer Surgery, East Midlands Cancer Alliance and NHSE

10.35 – 11.15

Panel: Exploring case studies of workforce innovation that achieve staff productivity and improve patient experience

• Embedding adaptability and new ways of working into the workforce to improve efficiency and reduce time pressures
• Developing knowledge, skills and capability in the workforce through the ACCEND (Aspirant Cancer Career and Education Development) programme
• Attracting and retaining staff through recruitment channels, longer term pipelines and a renewed focus on staff wellbeing to improve workforce experience
• Utilising data and population health analytics to foresee geographical demand and futureproof the workforce
• Measuring the impact of workforce innovations on patient experience 

Supported by Siemens Healthineers

Libby Potter, Head of Portfolio, Health Education England

Alistair Piggot, MR Business Manager, Siemens Healthineers 

Neil Woodhouse, MRI Manager, Blackpool Teaching Hospitals NHS Trust 

11.15 – 11.45

Morning break for refreshments & networking

11.45 – 12.50

Interactive Discussion Groups

Interactive roundtable discussions, each 25 mins in duration, so attendees can choose 2 of the following topics:

1. Fearless conversations, facilitating a systems approach to innovation in cancer care; using psychological safety to:

   Unlock our collective intelligence to respond to latest advances in cancer diagnoses and treatment

   Stimulate learning and positive risk taking for individual and team growth, and  

   Behavioural experiments and insights to incorporate into your practice immediately

   Supported by Novartis
   Rachel Cashman, Founder, Soircas Consultancy

2. Addressing chemotherapy capacity and challenges in a post covid world
   Supported by Bayer 
   Dr Lennard Lee, Academic Clinical Lecturer, Medical Oncologist, University of Oxford
3. Harnessing innovation in the diagnostic pathway 
   Session objectives:
   • Debate the key reasons for late cancer diagnosis and its implication on treatment options and patient outcomes
   • Using examples of partnerships, discuss how innovation in the patient pathway can help create capacity in the system and aim to help clinicians with earlier stage diagnosis
   • Define what future diagnostic collaborations could look like to ensure earlier stage diagnosis, quicker access to treatment and improved treatment pathways 

           Disclaimer: The session has been organised and funded by AstraZeneca

           David Brocklehurst, Head of Oncology, AstraZeneca UK
 

3. Utilising the latest genomics and cancer research to make care more personalised

4. Assessing the capabilities of data in improving cancer care

5. Maximising the efficiency and outcomes of MDTs to ensure more informed decisions are made and more personalised treatments delivered 

Lunch

13.50 – 14.30

Panel: Developing programmes and approaches to tackling inequality in access and outcomes

• Recognising the myriad of inequalities which dictate a person’s risk factors, ability to access early diagnostics and the quality of care in which they receive
• Adopting a data led approach in expanding targeted screening such as the Targeted Lung Health Check Programme
• Evaluating drivers of health inequalities which aren’t easily measured or uncovered through traditional data-led approaches
• Introducing direct patient representation from the communities which are underrepresented, raising awareness of specific issues faced and closing the inclusivity gap
• Examining the role of training and education to support the workforce in tackling health inequalities

Supported by EQRx
Dr John Howells, Consultant Radiologist and Clinical Director - The Targeted Lung Health Check Programme, Lancashire Teaching Hospitals NHS FT

Dr Maslah Amlin, National Clinical Advisor & Associate Director, Health Education England

Naser Turabi, Director of Evidence and Implementation, Cancer Research UK 

Christopher Keir, MD, MS, Senior Vice President, Medical Science Advocacy, EQRx 

14.30 – 15.10

Panel: Embedding a personalised approach into cancer care and treatment

• Discussing the results of the Cancer Quality of Life Survey and the National Cancer Patient Experience Surveys, ensuring patients voices are at the heart of their cancer journeys
• Creating personalised treatment plans by assessing patient responses as well as involving patients in the decision-making process and expanding health literacy
• Harnessing technology to enable seamless communication between patients and clinicians
• Providing comprehensive mental health support for patients and their families including after-care

Ceinwen Giles, Co-CEO, Shine Cancer Support and Chair NHS England Cancer Programme Patient & Public Voices Forum

Nikki Cannon, Transformation Lead - Personalised Care & Cancer Survivorship, Guy's and St Thomas' NHS FT 

15.10 – 15.35

Afternoon break for refreshments & networks

15.35 – 16.15

Panel: Expanding and improving routes of access to diagnosis to achieve the 28-day Faster Diagnosis Standard

• Examining a range of new initiatives in widening access to diagnosis such as the pharmacy pathway pilot, cancer hotlines, mobile screening units, non-GP referral and self-referral
• Ensuring operational agility in systems and workforce in order to deploy and deliver new approaches to diagnosis swiftly
• Exploring strategies to raise awareness of symptoms, refocusing on prevention and healthy lifestyle choices to create a society wide holistic approach to tackling cancer

Dr Amelia Randle, Clinical Chair, SWAG Cancer Alliance

16.20 – 16.50

Innovation Showcase
Hear the latest innovative processes in cancer care and delivery to aid in meeting targets. Each presenter will discuss their innovation for 10 minutes with time for discussion and shared learning afterwards.

Supported by Lilly

Transforming early multi-cancer detection through the NHS-Galleri Trial
Dr Thomas Round, Clinical Delivery Lead, Kings College London, NHS Galleri Trial

Unlocking the potential of community pharmacy to identify opportunistic presentations of disease

Andrew Walker, Lead Pharmacist for Oncology, The Mid Yorkshire Hospitals NHS Trust and Co-Chair, BOPA Community Pharmacy Committee

The impact of self-referral on prostate cancer pathways in improving early detection

Tim Dudderidge, Consultant Urologist, University Hospital Southampton

16.50 – 17.20

Discussion and shared learning

17.20 – 17.25

Closing remarks from the chair

download programme

.highlight { color: #20afad; } strong{font-weight: bold;} .ho{color:#fff;background-color: var(--button_hover_bg); } td, th { vertical-align: top; } .section-agenda p{ margin-bottom: 10px !important; } td:first-child { width:12%; } td:nth-child(2) { width:43%; } td:nth-child(3) { width:43%; } td{font-size: 16px;} p{margin: 0 0 0.8em;} td, th {padding: 15px 10px;} p.btn>a:hover { background-color: #00a79d !important; }

Lilly are supporting this meeting through sponsorship and have no control over the overall agenda or logistics of this event.